SK287791B6 - Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva - Google Patents

Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva Download PDF

Info

Publication number: SK287791B6
Authority: SK; Slovakia
Prior art keywords: ptx3; fgf; diseases caused; cells; tumor
Prior art date: 2000-11-08

Application number

SK562-2003A

Other languages

English (en)

Slovak (sk)

Other versions

SK5622003A3 (en

Inventor

Alberto Mantovani

Barbara Botazzi

Marco Presta

Marco Rusnati

Original Assignee

Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-08

Filing date

2001-11-08

Publication date

2011-10-04

2001-11-08 Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

2003-10-07 Publication of SK5622003A3 publication Critical patent/SK5622003A3/sk

2011-10-04 Publication of SK287791B6 publication Critical patent/SK287791B6/sk

Links

101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 title claims abstract description 92
BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 title claims abstract description 92
102100027351 Pentraxin-related protein PTX3 Human genes 0.000 title claims abstract description 92
201000010099 disease Diseases 0.000 title claims abstract description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
238000011282 treatment Methods 0.000 title claims abstract description 16
102000003974 Fibroblast growth factor 2 Human genes 0.000 title abstract description 78
108090000379 Fibroblast growth factor 2 Proteins 0.000 title abstract description 78
239000003102 growth factor Substances 0.000 title abstract description 15
230000004913 activation Effects 0.000 title abstract description 6
239000003814 drug Substances 0.000 claims abstract description 12
238000002360 preparation method Methods 0.000 claims abstract description 10
230000002265 prevention Effects 0.000 claims abstract description 6
230000033115 angiogenesis Effects 0.000 claims description 12
108700025763 PTX3 Proteins 0.000 claims description 10
108090000623 proteins and genes Proteins 0.000 claims description 10
101100352284 Homo sapiens PITX3 gene Proteins 0.000 claims description 9
101100031710 Homo sapiens PTX3 gene Proteins 0.000 claims description 9
239000002299 complementary DNA Substances 0.000 claims description 8
230000035755 proliferation Effects 0.000 claims description 8
230000004044 response Effects 0.000 claims description 8
238000002399 angioplasty Methods 0.000 claims description 7
208000037803 restenosis Diseases 0.000 claims description 7
206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
210000002950 fibroblast Anatomy 0.000 claims description 6
230000004663 cell proliferation Effects 0.000 claims description 5
230000003328 fibroblastic effect Effects 0.000 claims description 5
238000001415 gene therapy Methods 0.000 claims description 5
210000000329 smooth muscle myocyte Anatomy 0.000 claims description 5
239000013604 expression vector Substances 0.000 claims description 4
238000010276 construction Methods 0.000 claims description 2
201000001320 Atherosclerosis Diseases 0.000 claims 2
239000013600 plasmid vector Substances 0.000 claims 1
239000013603 viral vector Substances 0.000 claims 1
230000004071 biological effect Effects 0.000 abstract description 7
210000004027 cell Anatomy 0.000 description 33
206010028980 Neoplasm Diseases 0.000 description 28
230000027455 binding Effects 0.000 description 14
230000000694 effects Effects 0.000 description 13
230000001965 increasing effect Effects 0.000 description 12
206010029113 Neovascularisation Diseases 0.000 description 11
210000002889 endothelial cell Anatomy 0.000 description 10
206010027476 Metastases Diseases 0.000 description 9
238000011534 incubation Methods 0.000 description 9
239000002246 antineoplastic agent Substances 0.000 description 8
230000009401 metastasis Effects 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
238000002474 experimental method Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
230000003993 interaction Effects 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
229940041181 antineoplastic drug Drugs 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
230000002018 overexpression Effects 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108010074051 C-Reactive Protein Proteins 0.000 description 5
102100032752 C-reactive protein Human genes 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
230000017363 positive regulation of growth Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000001464 adherent effect Effects 0.000 description 4
230000001093 anti-cancer Effects 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
210000003711 chorioallantoic membrane Anatomy 0.000 description 4
238000000034 method Methods 0.000 description 4
230000002297 mitogenic effect Effects 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
230000002792 vascular Effects 0.000 description 4
206010003210 Arteriosclerosis Diseases 0.000 description 3
102000009123 Fibrin Human genes 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
230000001772 anti-angiogenic effect Effects 0.000 description 3
210000002403 aortic endothelial cell Anatomy 0.000 description 3
208000011775 arteriosclerosis disease Diseases 0.000 description 3
230000002917 arthritic effect Effects 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
208000037976 chronic inflammation Diseases 0.000 description 3
230000006020 chronic inflammation Effects 0.000 description 3
229950003499 fibrin Drugs 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 3
229960005314 suramin Drugs 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102100030497 Cytochrome c Human genes 0.000 description 2
108010075031 Cytochromes c Proteins 0.000 description 2
108091008794 FGF receptors Proteins 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
102000003777 Interleukin-1 beta Human genes 0.000 description 2
108090000193 Interleukin-1 beta Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
101100192405 Mus musculus Ptx3 gene Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000006427 angiogenic response Effects 0.000 description 2
238000011122 anti-angiogenic therapy Methods 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
230000003305 autocrine Effects 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
150000001982 diacylglycerols Chemical class 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
210000001365 lymphatic vessel Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
101150019331 FGF2 gene Proteins 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
102100037362 Fibronectin Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010052399 Neuroendocrine tumour Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
108090000054 Syndecan-2 Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000005773 cancer-related death Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
230000008355 cartilage degradation Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000034196 cell chemotaxis Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
238000011496 digital image analysis Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000003278 egg shell Anatomy 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
201000011519 neuroendocrine tumor Diseases 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000021048 nutrient requirements Nutrition 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
102000041715 pentraxin family Human genes 0.000 description 1
108091075331 pentraxin family Proteins 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000004218 vascular function Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Marine Sciences & Fisheries (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)

SK562-2003A 2000-11-08 2001-11-08 Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva SK287791B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2000RM000578A IT1317930B1 (it)	2000-11-08	2000-11-08	Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PCT/IT2001/000563 WO2002038169A1 (en)	2000-11-08	2001-11-08	Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Publications (2)

Publication Number	Publication Date
SK5622003A3 SK5622003A3 (en)	2003-10-07
SK287791B6 true SK287791B6 (sk)	2011-10-04

Family

ID=11454983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK562-2003A SK287791B6 (sk)	2000-11-08	2001-11-08	Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva

Country Status (21)

Country	Link
US (1)	US7858577B2 (cs)
EP (1)	EP1331940B1 (cs)
JP (1)	JP4167061B2 (cs)
KR (1)	KR100822357B1 (cs)
CN (1)	CN1304047C (cs)
AT (1)	ATE322906T1 (cs)
AU (2)	AU2251302A (cs)
BR (1)	BR0115190A (cs)
CA (1)	CA2428176C (cs)
CY (1)	CY1106092T1 (cs)
CZ (1)	CZ299673B6 (cs)
DE (1)	DE60118769T2 (cs)
DK (1)	DK1331940T3 (cs)
ES (1)	ES2261515T3 (cs)
HU (1)	HU229100B1 (cs)
IT (1)	IT1317930B1 (cs)
MX (1)	MXPA03004005A (cs)
PL (1)	PL205925B1 (cs)
PT (1)	PT1331940E (cs)
SK (1)	SK287791B6 (cs)
WO (1)	WO2002038169A1 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1298487B1 (it) *	1997-12-19	2000-01-10	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) *	2002-02-28	2003-08-28	Sigma Tau Ind Farmaceuti	Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) *	2002-04-08	2003-10-08	Sigma Tau Ind Farmaceuti	Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) *	2003-12-23	2005-06-24	Sigma Tau Ind Farmaceuti	Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
WO2005080981A1 (ja) *	2004-02-25	2005-09-01	Perseus Proteomics Inc.	血管障害の程度の判定方法
ITRM20040489A1 (it)	2004-10-08	2005-01-08	Sigma Tau Ind Farmaceuti	Pentraxina lunga ptx3 deglicosilata o desialidata.
JP5427415B2 (ja) *	2006-01-24	2014-02-26	シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ	Ｆｇｆ２結合性ペプチドおよびそれらの使用
EP1832295A1 (en) *	2006-03-10	2007-09-12	Tecnogen S.P.A.	Use of PTX3 for the treatment of viral diseases
PT2012816E (pt)	2006-05-02	2012-08-17	Sigma Tau Ind Farmaceuti	Uso de timosina 1, isolada ou em combinação com ptx3 ou ganciclovir, para o tratamento da infeção por citomegalovírus
WO2013191280A1 (ja) *	2012-06-22	2013-12-27	国立大学法人東京大学	全身性炎症反応症候群の治療又は予防剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06506195A (ja) *	1991-01-14	1994-07-14	ニューヨーク　ユニバシテイ	サイトカイン誘導タンパク質、ｔｓｇ−１４、そのためのｄｎａコード化およびその使用
IT1298487B1 (it) *	1997-12-19	2000-01-10	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

2000
- 2000-11-08 IT IT2000RM000578A patent/IT1317930B1/it active
2001
- 2001-11-08 ES ES01993471T patent/ES2261515T3/es not_active Expired - Lifetime
- 2001-11-08 HU HU0400541A patent/HU229100B1/hu not_active IP Right Cessation
- 2001-11-08 AU AU2251302A patent/AU2251302A/xx active Pending
- 2001-11-08 KR KR1020037006278A patent/KR100822357B1/ko not_active Expired - Fee Related
- 2001-11-08 MX MXPA03004005A patent/MXPA03004005A/es active IP Right Grant
- 2001-11-08 DE DE60118769T patent/DE60118769T2/de not_active Expired - Lifetime
- 2001-11-08 JP JP2002540751A patent/JP4167061B2/ja not_active Expired - Fee Related
- 2001-11-08 CZ CZ20031179A patent/CZ299673B6/cs not_active IP Right Cessation
- 2001-11-08 CN CNB018185630A patent/CN1304047C/zh not_active Expired - Fee Related
- 2001-11-08 PT PT01993471T patent/PT1331940E/pt unknown
- 2001-11-08 SK SK562-2003A patent/SK287791B6/sk not_active IP Right Cessation
- 2001-11-08 DK DK01993471T patent/DK1331940T3/da active
- 2001-11-08 EP EP01993471A patent/EP1331940B1/en not_active Expired - Lifetime
- 2001-11-08 WO PCT/IT2001/000563 patent/WO2002038169A1/en not_active Ceased
- 2001-11-08 BR BR0115190-8A patent/BR0115190A/pt active Search and Examination
- 2001-11-08 US US10/416,225 patent/US7858577B2/en not_active Expired - Fee Related
- 2001-11-08 AT AT01993471T patent/ATE322906T1/de active
- 2001-11-08 CA CA2428176A patent/CA2428176C/en not_active Expired - Fee Related
- 2001-11-08 PL PL365292A patent/PL205925B1/pl unknown
- 2001-11-08 AU AU2002222513A patent/AU2002222513B8/en not_active Ceased
2006
- 2006-06-05 CY CY20061100719T patent/CY1106092T1/el unknown

Also Published As

Publication number	Publication date
US7858577B2 (en)	2010-12-28
KR20030061396A (ko)	2003-07-18
AU2002222513B8 (en)	2006-11-23
JP2004513151A (ja)	2004-04-30
CA2428176A1 (en)	2002-05-16
US20040023879A1 (en)	2004-02-05
HU229100B1 (en)	2013-07-29
HUP0400541A3 (en)	2006-01-30
HUP0400541A2 (hu)	2004-05-28
AU2002222513B2 (en)	2006-10-26
DK1331940T3 (da)	2006-08-14
WO2002038169A1 (en)	2002-05-16
EP1331940B1 (en)	2006-04-12
IT1317930B1 (it)	2003-07-15
CY1106092T1 (el)	2011-06-08
CN1473050A (zh)	2004-02-04
SK5622003A3 (en)	2003-10-07
PL365292A1 (en)	2004-12-27
PL205925B1 (pl)	2010-06-30
JP4167061B2 (ja)	2008-10-15
MXPA03004005A (es)	2004-05-05
CZ299673B6 (cs)	2008-10-15
KR100822357B1 (ko)	2008-04-16
BR0115190A (pt)	2004-02-03
HK1061209A1 (en)	2004-09-10
PT1331940E (pt)	2006-07-31
DE60118769D1 (de)	2006-05-24
ATE322906T1 (de)	2006-04-15
ITRM20000578A1 (it)	2002-05-08
CA2428176C (en)	2013-02-05
ES2261515T3 (es)	2006-11-16
CN1304047C (zh)	2007-03-14
AU2251302A (en)	2002-05-21
DE60118769T2 (de)	2007-01-04
CZ20031179A3 (cs)	2003-11-12
EP1331940A1 (en)	2003-08-06

Legal Events

Date	Code	Title	Description
2017-08-02	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20161108

Publication	Publication Date	Title
Nyberg et al.	2005	Endogenous inhibitors of angiogenesis
Reilly et al.	1998	Regulation of astrocyte GFAP expression by TGF‐β1 and FGF‐2
Albini et al.	1996	The angiogenesis induced by HIV–1 Tat protein is mediated by the Flk–1/KDR receptor on vascular endothelial cells
Lambert et al.	2004	TIMPs as multifacial proteins
JP3854307B2 (ja)	2006-12-06	細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
Makinde et al.	2008	Intra and extravascular transmembrane signalling of angiopoietin‐1‐Tie2 receptor in health and disease
Shu et al.	2016	Ablation of perlecan domain 1 heparan sulfate reduces progressive cartilage degradation, synovitis, and osteophyte size in a preclinical model of posttraumatic osteoarthritis
JP4993834B2 (ja)	2012-08-08	細胞増殖および血管形成の調節物質、その使用方法および特定方法
US5744492A (en)	1998-04-28	Method for inhibiting angiogenesis
Olsson et al.	2004	The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization
SK287791B6 (sk)	2011-10-04	Použitie dlhého pentraxin PTX3 alebo jeho funkčných derivátov alebo domén na prípravu liečiva
Hibino et al.	2005	Laminin α5 chain metastasis-and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44
AU2002222513A1 (en)	2002-07-25	Use of the long pentraxin PTX3 for the treatment of diseases caused by an altered activation of the growth factor FGF-2
Leenders	1998	Targetting VEGF in anti‐angiogenic and anti‐tumour therapy: Where are we now?
Hatzi et al.	2002	N‐myc oncogene overexpression down‐regulates leukemia inhibitory factor in neuroblastoma
US20050043230A1 (en)	2005-02-24	Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases
Motozawa et al.	2018	Functional comparison of high and low molecular weight basic fibroblast growth factors
Srinivasan	2025	Regulatory Role and Significance of Class III SLRPs: Osteoglycin, Epiphycan, and Opticin
HK1061209B (en)	2007-09-14	Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
JACKSON et al.	1997	Angiogenesis and the Endothelial Cell Cycle
Guo	2003	CD105 expression and its effects on TGF-β signalling, angiogenesis and cell behaviour